uu.seUppsala universitets publikasjoner
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis: a prospective, open-label, multi-centre study
Karolinska Inst, Dept Med Solna, Infect Dis Unit, SE-17176 Stockholm, Sweden; Dept Communicable Dis Control & Prevent, SE-11891 Stockholm, Sweden.
Uppsala universitet, Medicinska och farmaceutiska vetenskapsområdet, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD). Karolinska Inst, Dept Med Solna, Infect Dis Unit, SE-17176 Stockholm, Sweden.
Karolinska Inst, Unit Clin Therapy Res Inflammatory Dis ClinTRID, SE-17176 Stockholm, Sweden.
Karlstad Cty Hosp, Dept Infect Dis, SE-65185 Karlstad, Sweden.
Vise andre og tillknytning
2014 (engelsk)Inngår i: Travel Medicine and Infectious Disease, ISSN 1477-8939, E-ISSN 1873-0442, Vol. 12, nr 2, s. 134-42Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

BACKGROUND: Hepatitis A vaccine is the most frequently used travel vaccine, yet data are scarce about its ability to induce protection in patients with concurrent immunosuppressive treatment. We assessed the immunogenicity of this vaccine in rheumatoid arthritis (RA) patients treated with tumour necrosis factor-inhibitors (TNFi) and/or methotrexate (MTX).

METHODS: Hepatitis A vaccine was administered to non-immune RA patients at 0 and 6 months. Hepatitis A virus (HAV) antibodies were assessed at 0, 1, 6, 7, 12, and 24 months with a quantitative Chemiluminescent Microparticle Immuno Assay (CMIA) for HAV-IgG. Samples from month 1, 6, and 7 were, in addition, analysed with a microparticle EIA (MEIA) for anti-HAV IgM + IgG.

RESULTS: The final study population consisted of 53 patients treated with TNFi (n = 15), TNFi + MTX (n = 21) or MTX (n = 17). One and six months after the first dose, 10% and 33% of the patients had attained seroprotection. One and six months after the second dose 83% and 72% were seroprotected. At month 24, 86% of the vaccinees showed protective levels.

CONCLUSIONS: Two doses of hepatitis A vaccine at a 6-month interval provided protection for most immunosuppressed RA patients. A single dose does not seem to afford sufficient protection to this group of patients.

sted, utgiver, år, opplag, sider
2014. Vol. 12, nr 2, s. 134-42
Emneord [en]
Hepatitis A, Vaccination, Immunosuppression, Rheumatoid arthritis, TNF-inhibitors
HSV kategori
Identifikatorer
URN: urn:nbn:se:uu:diva-245327DOI: 10.1016/j.tmaid.2014.01.005ISI: 000349278600004PubMedID: 24529746OAI: oai:DiVA.org:uu-245327DiVA, id: diva2:791116
Tilgjengelig fra: 2015-02-26 Laget: 2015-02-26 Sist oppdatert: 2017-12-04bibliografisk kontrollert

Open Access i DiVA

fulltext(665 kB)66 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 665 kBChecksum SHA-512
620074ce8562cd54d40a30da2dc3af2318b5b74bc96f897efa502a3999e73ae697053e8c1c8612f57d4263e110a6ff586612c3224658371c42baf77c0a05c68a
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed
Av organisasjonen
I samme tidsskrift
Travel Medicine and Infectious Disease

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 66 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 529 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf